Shares of the clinical-stage biotech Geron Corporation (NASDAQ: GERN) are up by double digits for the second day in a row on no apparent news. What's going on?While the company hasn't released any material news this week to explain this sudden move higher, Geron's stock might be responding to two recent developments:Image source: Getty Images.Continue reading